Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Estrella Immunopharma, Inc. (ESLA : NSDQ)

• Company Description    Estrella Immunopharma Inc is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS(R) T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. The company's lead product candidate includes EB103 and EB104. Estrella Immunopharma Inc., formerly known as TradeUP Acquisition Corp., is based in NEW YORK. Number of Employees: 3

• Price / Volume Information    Yesterday's Closing Price: $2.93 Daily Weekly Monthly 20 Day Moving Average: 511,973 shares Shares Outstanding: 37.07 (millions) Market Capitalization: $108.60 (millions) Beta: 0.51 52 Week High: $3.15 52 Week Low: $0.70 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 127.13% 121.18% 12 Week 221.98% 208.63% Year To Date 144.17% 113.43%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 5858 Horton Street Suite 370 - Emeryville,CA 95608 USA ph: 510-318-9098 fax: - ir@estrellabio.com http://www.estrellabio.com

• General Corporate Information    Officers Cheng Liu - Chief Executive Officer Hong Zhang - Chairperson Peter Xu - Chief Financial Officer Marsha Roberts - Director Fan Wu - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 297584104 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/13/25 Share - Related Items Shares Outstanding: 37.07 Most Recent Split Date: (:1) Beta: 0.51 Market Capitalization: $108.60 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -15.38% vs. Previous Quarter: -150.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - - 03/31/25 - -1,132.38 ROA 09/30/25 - - 06/30/25 - -358.54 03/31/25 - -273.91 Current Ratio 09/30/25 - - 06/30/25 - 0.16 03/31/25 - 0.22 Quick Ratio 09/30/25 - - 06/30/25 - 0.16 03/31/25 - 0.22 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - -0.17 03/31/25 - -0.05 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Capital 09/30/25 - - 06/30/25 - - 03/31/25 - -

Powered by Zacks Investment Research ©